REDWOOD CITY, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced that the Centers for Medicare and Medicaid Services (CMS) has published a ...
Please provide your email address to receive an email when new articles are posted on . It has been nearly 3 years since the first ranibizumab biosimilar was approved for use in the U.S. Byooviz ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results